(Q44100013)

29 November 2017

title

Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients (English)

1 reference

29 November 2017

0 references

2

1 reference

29 November 2017

3

1 reference

29 November 2017

Jose Castellote

6

0 references

author name string

Marta Bodro

1

1 reference

29 November 2017

Carme Baliellas

4

1 reference

29 November 2017

Jordi Niubó

5

1 reference

29 November 2017

Joan Fabregat

7

1 reference

29 November 2017

Antoni Rafecas

8

1 reference

29 November 2017

Jordi Carratalà

9

1 reference

29 November 2017

publication date

1 September 2012

1 reference

29 November 2017

published in

Liver Transplantation

1 reference

29 November 2017

volume

18

1 reference

29 November 2017

issue

9

1 reference

29 November 2017

page(s)

1093-1099

1 reference

Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis.

29 November 2017

cites work

1 reference

Infection in solid-organ transplant recipients

21 January 2018

1 reference

Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials.

21 January 2018

1 reference

Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.

21 January 2018

1 reference

Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients

21 January 2018

1 reference

Cytomegalovirus infection after liver transplantation: current concepts and challenges

21 January 2018

1 reference

Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.

21 January 2018

1 reference

Pre-emptive oral ganciclovir can reduce the risk of cytomegalovirus disease in liver transplant recipients

21 January 2018

1 reference

Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients

21 January 2018

1 reference

Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.

21 January 2018

1 reference

GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients.

21 January 2018

1 reference

International consensus guidelines on the management of cytomegalovirus in solid organ transplantation

21 January 2018

1 reference

Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial

21 January 2018

1 reference

Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients

21 January 2018

1 reference

Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease

21 January 2018

1 reference

Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts

21 January 2018

1 reference

Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy

21 January 2018

1 reference

Unraveling the biologic basis of late-onset cytomegalovirus disease in high-risk organ transplant recipients

21 January 2018

1 reference

Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis

21 January 2018

1 reference

Late-onset cytomegalovirus disease in patients with solid organ transplant

21 January 2018

1 reference

Delayed-onset primary cytomegalovirus disease after liver transplantation

21 January 2018

1 reference

American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation

21 January 2018

1 reference

Definitions of cytomegalovirus infection and disease in transplant recipients

21 January 2018

1 reference

Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review

21 January 2018

1 reference

Preemptive therapy for cytomegalovirus based on real-time measurement of viral load in liver transplant recipients

21 January 2018

1 reference

Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment.

21 January 2018

1 reference

Prophylaxis, preemption and drug resistance in CMV infection: too little, too much or just right?

21 January 2018

1 reference

A new strategy of delayed long-term prophylaxis could prevent cytomegalovirus disease in (D+/R-) solid organ transplant recipients.

21 January 2018

1 reference

The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients

21 January 2018

1 reference

IMPACT trial results should not change current standard of care of 100 days for cytomegalovirus prophylaxis

21 January 2018

1 reference

Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study

21 January 2018

1 reference

Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/LT.23460

1 reference

29 November 2017

1 reference